Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review
| Autor: | Kirsi Taimen, Laura Pirilä, Ia Kohonen, Heikki Relas, Samu Heino, Riikka Huovinen, Arno Hänninen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment adverse drug reaction 030204 cardiovascular system & hematology chemotherapy Chest pain vasculitis 03 medical and health sciences 0302 clinical medicine Breast cancer febrile neutropoenia Rheumatology Internal medicine Medicine Arteritis Adverse effect 030203 arthritis & rheumatology Chemotherapy business.industry medicine.disease Chemotherapy regimen 3. Good health Discontinuation large vessel vasculitis Original Article granulocyte colony-stimulating factor medicine.symptom business Vasculitis aortitis |
| Zdroj: | Rheumatology Advances in Practice |
| ISSN: | 2514-1775 |
| DOI: | 10.1093/rap/rkaa004 |
| Popis: | Objective Patients receiving chemotherapy are prone to neutropoenic infections, presenting with non-specific symptoms such as a high fever and elevated inflammatory parameters. Large-vessel vasculitis (LVV) may have a similar clinical presentation and should be included in differential diagnostics. A few published case reports and adverse event reports suggest a causal association between LVV and the use of granulocyte colony-stimulating factor (G-CSF) and chemotherapy. Our objective was to evaluate the relationship between LVV, G-CSF and chemotherapy. Methods Between 2016 and 2018, we identified six patients in Finland with probable drug-induced LVV associated with G-CSF and chemotherapy. All six patients had breast cancer. A systematic literature review was performed according to PRISMA guidelines using comprehensive search terms for cancer, chemotherapy, G-CSF and LVV. Results The literature search identified 18 similar published case reports, of which most were published after 2014. In all patients combined (n = 24), the time delay from the last drug administration to the LVV symptoms was on average 5 days with G-CSF (range = 1–8 days) and 9 days with chemotherapy (range = 1–21 days). Common symptoms were fever (88%), neck pain (50%) and chest pain (42%). Based on imaging, 17/24 (71%) had vascular inflammation in the thoracic aorta and supra-aortic vessels, but 5/24 (21%) reportedly had inflammation limited to the carotid area. Conclusion This review suggests that LVV may be a possible serious adverse event associated with G-CSF and chemotherapy. Successful management of drug-induced LVV requires early identification, through diagnostic imaging, and discontinuation of the drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|